No Man

Sign in

Join Free
Post RFQ

Romidepsin

TypeName: Business Offer

Category:

Country: United States

Summary: Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.https://www.creative-peptides.com/product/romidepsin-item-10-101-186-33671.html

Description:

OfferId: 722

Name:Cathy Miller

Telphone:

Email:[email protected]